A Synergistic Effect of Serotonin Transporter Gene Polymorphism and Smoking in Association with CHD

Tadao Arinami; Tsuyuka Ohtsuki; Kimiko Yamakawa-Kobayashi; Hiroshi Amemiya; Hideomi Fujiwara; Ken-ichi Kawata; Hiroki Ishiguro; Hideo Hamaguchi

doi:10.1055/s-0037-1614586

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 81(06): 853-856
DOI: 10.1055/s-0037-1614586

Letters to the Editor

Schattauer GmbH

A Synergistic Effect of Serotonin Transporter Gene Polymorphism and Smoking in Association with CHD

Tadao Arinami

,

Tsuyuka Ohtsuki

,

Kimiko Yamakawa-Kobayashi

,

Hiroshi Amemiya

¹From the Department of Medical Genetics, Institute of Basic Medical Sciences, University of Tsukuba, Division of Cardiology and Tsuchiura Kyodo General Hospital, Japan

,

Hideomi Fujiwara

¹From the Department of Medical Genetics, Institute of Basic Medical Sciences, University of Tsukuba, Division of Cardiology and Tsuchiura Kyodo General Hospital, Japan

,

Ken-ichi Kawata

²Rural Health Care Center, Tsuchiura Kyodo General Hospital, Japan

,

Hiroki Ishiguro

,

Hideo Hamaguchi

› Institutsangaben

Abstract

Summary

Serotonin induces vasoconstriction in the presence of atherosclerotic lesions. Platelets acquire serotonin from the extracellular space by serotonin transporter and release it following aggregation. There is a functional polymorphism in the serotonin transporter (5-HTT) gene promoter associated with transcriptional efficacy and plasma serotonin levels. To examine whether the polymorphism is associated with coronary heart disease (CHD) in the Japanese, we analyzed 144 male CHD patients with an onset age before 65 and 222 apparently healthy men. The L allele was observed significantly more frequently in the CHD patients (26%) than in the control subjects (19%); the odds ratio was 1.48 (p <0.03). A significant interaction between the polymorphism and smoking was observed for CHD (p = 0.03), suggesting that the two have a synergistic effect on CHD. Odds ratio of the combination of the L allele and smoking was 1.95 (p <0.003). The 5-HTT gene promoter polymorphism may play a role in susceptibility to CHD, particularly when it is combined with smoking.

Volltext

Referenzen

References
1 Fricchione GL, Bilfinger TV, Hartman A, Liu Y, Stefano GB. Neuroimmunologic implications in coronary artery disease. Adv Neuroimmunol 1996; 6: 131-42.
2 Hayreh SS, Piegors DJ, Heistad DD. Serotonin-induced constriction of ocular arteries in atherosclerotic monkeys. Implications for ischemic disorders of the retina and optic nerve head. Arch Ophthalmol 1997; 115: 220-8.
3 van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79: 116-24.
4 Golino P, Piscione F, Benedict CR, Anderson HV, Cappelli-Bigazzi M, Indolfi C, Condorelli M, Chiariello M, Willerson JT. Local effect of serotonin released during coronary angioplasty. N Eng J Med 1994; 330: 523-8.
5 Geerling RA, de Bruin RW, Scheringa M, Bonthuis F, JN IJ, Marquet RL. Ketanserin reduces graft arteriosclerosis after allogeneic aorta transplantation in rats. J Cardiovasc Pharmacol 1996; 27: 307-11.
6 Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
7 Hanna GL, Himle JA, Curtis GC, Koram DQ, Weele JV, Leventhal BL, Cook Jr EH. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 1998; 18: 102-11.
8 Gelernter J, Kranzler H, Coccaro EF, Siever LJ, New AS. Serotonin Transporter Protein Gene Polymorphism and Personality Measures in African American and European American Subjects. Am J Psychiatry 1998; 155: 1332-8.
9 Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B, Tan X, Easteal S. An association study of a functional polymorphism of the serotonin transporter gene with personality and psychiatric symptoms. Mol Psychiatry 1998; 3: 449-51.
10 Mazzanti CM, Lappalainen J, Long JC, Bengel D, Naukkarinen H, Eggert M, Virkkunen M, Linnoila M, Goldman D. Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Arch Gen Psychiatry 1998; 55: 936-40.
11 Yamanouchi Y, Arinami T, Tsuchiya S, Miyazaki R, Takaki H, Takano T, Hamaguchi H. Apolipoprotein E5 and E7 in apparently healthy Japanese males: frequencies and relation to plasma lipid levels. Jpn J Hum Genet 1994; 39: 315-25.
12 Terwilliger JD, Ott J.. Handbook of human genetic linkage. Baltimore: The Johns Hopkins University Press; 1994
13 Delbruck SJ, Wendel B, Grunewald I, Sander T, Morris-Rosendahl D, Crocq MA, Berrettini WH, Hoehe MR. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet Cell Genet 1997; 79: 214-20.
14 Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3: 21-8.
15 Gering SA, Folts JD. Exacerbation of acute platelet thrombus formation in stenosed dog coronary arteries with smoke from a non-tobacco-burning cigarette. J Lab Clin Med 1990; 116: 728-36.
16 Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Glantz SA, Parmley WW. Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits. J Am Coll Cardiol 1993; 21: 225-32.
17 Lilienberg G, Venge P. Platelet adhesion in patients prone to arterial and venous thrombosis – the impact of gender, smoking and heredity. Scand J Clin Lab Invest 1998; 58: 279-86.